BGI Genomics (300676.SZ) has announced a forecasted pre-tax loss, expecting a net loss of 750 million to 920 million yuan in 2024, turning from profit to loss.
BGI Genomics (300676.SZ) released its 2024 performance forecast, with the company expecting its 2024 attributable...
BGI Genomics(300676.SZ) released its 2024 performance forecast, with the company expecting a net loss attributable to shareholders of the listed company of 750 million to 920 million yuan in 2024, turning from profit to loss; and a net loss of 730 million to 950 million yuan after deducting non-recurring gains and losses, also turning from profit to loss.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
